Business Segments Northwest Biotherapeutics, Inc. Börse Stuttgart
Stocks
NBYB
US66737P6007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1450 EUR | +11.54% |
|
-9.38% | -29.61% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discover and Develop Innovative Immunotherapies for Cancer | 1M | 1.68M | 1.93M | 1.38M | 1.38M | |||||
Total Assets | 40.16M | 31.32M | 27.86M | 26.73M | 81.29M | |||||
Interest Expense | -5.01M | -6.07M | -5.24M | -7.77M | -8.7M | |||||
Income Tax Expense | - | - | - | - | -537K | |||||
CAPEX | -6.02M | -2.9M | -3.44M | -1.01M | -1.5M | |||||
EBT | 179M | -105M | -62.6M | -83.78M | -60.7M | |||||
D&A | 324K | 1.5M | 1.73M | 2.04M | 2.34M | |||||
Operating Income | -52.7M | -67.18M | -55.51M | -66.51M | -59.91M | |||||
Net Income | 179M | -105M | -62.6M | -83.78M | -60.16M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 1M | 1.68M | 1.93M | 1.38M | 1.38M | |||||
Total Assets | 40.16M | 31.32M | 27.86M | 26.73M | 81.29M | |||||
Interest Expense | -5.01M | -6.07M | -5.24M | -7.77M | -8.7M | |||||
Income Tax Expense | - | - | - | - | -537K | |||||
D&A | 324K | 1.5M | 1.73M | 2.04M | 2.34M | |||||
CAPEX | -6.02M | -2.9M | -3.44M | -1.01M | -1.5M | |||||
Net Income | 179M | -105M | -62.6M | -83.78M | -60.16M | |||||
EBT | 179M | -105M | -62.6M | -83.78M | -60.7M | |||||
Operating Income | -52.7M | -67.18M | -55.51M | -66.51M | -59.91M |
Select your edition
All financial news and data tailored to specific country editions
